Drug intelligence / Profile preview

CTH-300 series

Development stage: Preclinical
Lead developer: Cartherics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

CTH-300 series is a preclinical-stage platform of induced T-cell (iT) chimeric antigen receptor (CAR) T-cell therapies developed by Cartherics. These therapies are derived from induced pluripotent stem cells (iPSCs) and incorporate gene knockout technology to enhance therapeutic potential. The series is designed for the treatment of cancer, utilizing an "off-the-shelf" approach to cellular immunotherapy. While the specific molecular targets for the CTH-300 series have not been publicly specified, the platform integrates gene editing with iPSC-derived cell lines to create standardized, scalable T-cell products.

Targets

TAG-72

Beyond the preview

Go deeper on CTH-300 series.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTH-300 series.

Explore the full profile